Navigation Links
New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC
Date:10/8/2007

- A Total of 13 Abstracts for Eight Compounds Being Presented - - Investor Briefing to be Webcast on October 24, 2007 at 6:00 PM PDT -

SOUTH SAN FRANCISCO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced that data from ongoing phase 2 trials of XL880 and XL647 in papillary renal cell carcinoma and non-small cell lung cancer, respectively, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Francisco. In addition, phase 1 data for XL184, which inhibits MET, VEGFR2 and RET, will also be presented. In total, 13 abstracts for eight compounds have been accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518.

"With 13 abstracts covering eight clinical-stage compounds, the 2007 AACR-NCI-EORTC meeting is an important opportunity to highlight the breadth and depth of our pipeline," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Critical to our goal of building a world-class oncology franchise is the rapid advancement of the 14 compounds currently in the clinic and the continued ability to advance additional compounds into development. We believe our strong presence at this meeting is evidence of our productivity. Three of the phase 1 compounds that will be discussed were preclinical compounds at this time last year and we will present phase 2 data from trials that were initiated less than 18 months ago."

Exelixis will hold a briefing for investors and analysts on Wednesday, October 24, 2007, from 6:00-8:00 p.m. PDT / 9:00-11:00 p.m. EDT. During the briefing, Exelixis management will review data for XL647, XL880 and XL184, in addition to other Exelixis compounds. This webcast may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com. An archive of the webcast will be available until 8:59 p.m. PST/11:59 p.m. EST on November 24, 2007. Access numbers for the replay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international). The replay passcode is 86296035.

The full list of abstracts to be presented at the meeting follows:

Phase 2 Clinical Abstracts

-- A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients

(pts) with papillary renal carcinoma (PRC) (Abstract #B249)

-- A Phase II study of XL647 in Patients with Non-Small Cell Lung Cancer

(NSCLC) Enriched for Presence of EGFR Mutations (Abstract #B124)

Phase 1 Clinical Abstracts

-- A phase 1 dose-escalation study of the safety and pharmacokinetics (PK)

of XL184, a VEGFR and MET kinase inhibitor, administered orally to

patients (pts) with advanced malignancies (Abstract #A152)

-- A phase I dose-escalation study of the safety, pharmacokinetics, and

pharmacodynamics of XL820 administered orally daily (QD) or twice daily

(BID) to patients (pts) with solid malignancies (Abstract #B69)

-- Targeting aberrant PI3K pathway signaling with XL147, a potent,

selective and orally bioavailable PI3K inhibitor (Abstract #C205)

-- Biomarker development for XL765, a potent and selective oral dual

inhibitor of PI3K and mTOR currently being administered to patients in

a Phase I clinical trial (Abstract #B265)

-- A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a

novel spectrum selective kinase inhibitor, administered orally daily to

patients with advanced solid malignancies (ASM) (Abstract #B242)

-- A Phase I dose-escalation study of the safety, pharmacokinetics (PK)

and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor,

administered daily to patients (pts) with advanced malignancies

(Abstract #B248)

Preclinical Abstracts

-- XL820 inhibits mutated forms of KIT associated with drug resistance

(Abstract #B237)

-- In vitro and in vivo potentiation of cytotoxic therapy by XL844, an

orally bioavailable inhibitor of Chk1 and Chk2 (Abstract #B228)

-- XL518, a Potent Selective Orally Bioavailable MEK1 Inhibitor,

Downregulates the RAS/RAF/MEK/ERK Pathway In Vivo, Resulting in Tumor

Growth Inhibition and Regression in Pre-Clinical Models (Abstract

#C209)

-- Potentiating the antitumor effects of chemotherapy with the selective

PI3K inhibitor XL147 (Abstract #C199)

-- XL765 targets tumor growth, survival, and angiogenesis in preclinical

models by dual inhibition of PI3K and mTOR (Abstract #B250)

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
Breaking Medicine News(10 mins):